← Back to Search

Stem Cell Therapy

Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI (SCI Trial)

Phase 1
Waitlist Available
Led By Joseph Ciacci, MD
Research Sponsored by Neuralstem Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 60
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment for spinal cord injury using stem cells.

Eligible Conditions
  • Spinal Cord Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Graft survival in the transplant site as determined by MRI (for Group A) and via autopsy, if one is completed.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Surgical implantation of human spinal cord stem cellsExperimental Treatment1 Intervention
Surgical implantation of human spinal cord derived neural stem cells.

Find a Location

Who is running the clinical trial?

Neuralstem Inc.Lead Sponsor
6 Previous Clinical Trials
537 Total Patients Enrolled
Joseph Ciacci, MDPrincipal InvestigatorUCSD Medical Center, Division of Neurosurgery
1 Previous Clinical Trials
7 Total Patients Enrolled
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top